Women's Health Series: Endometriosis--How Will New Therapies Compare with Current Market Leaders?

Published by: Decision Resources

Published: Sep. 12, 2008 - 20 Pages

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Overview of Endometriosis

Etiology and Pathophysiology

Symptoms

Current Therapies

Sanofi -Aventis’s Danocrine

Abbott Laboratories/Takeda Pharmaceutical/TAP Pharmaceutical’s Lupron/Lupron Depot

AstraZeneca’s Zoladex

Pfi zer’s Synarel

Pfi zer’s Provera/Depo-Provera

Current Surgical Treatments for Endometriosis

Medical Practice

Mild Endometriosis

Moderate Endometriosis

Severe Endometriosis

Emerging Therapies

Neurocrine Biosciences’ Elagolix

Repros Therapeutics’ Proellex (CDB-4124)

KV Pharmaceuticals’ FP-1096

2007 Sales and Outlook for the Endometriosis Market

Tables

1. Current Treatments for Endometriosis

2. Emerging Therapies in Development for Endometriosis

3. Sales of Leading Agents to Treat Endometriosis, 2007

Figures

1. Obstetrician/Gynecologist-Estimated Percentages of Endometriosis Cases by Disease Severity

2. Specialists’ Estimate of Percentage of Patients with Endometrial Implants, by Anatomical Location

3. Survey Question: What Percentage of Your Patients Have the Following Endometriosis Symptoms?

4. Survey Question: Indicate Your Preferred First-, Second-, and Third-Line Treatments for Mild Endometriosis

5. Survey Question: Indicate Your Preferred First-, Second-, and Third-Line Treatments for Moderate Endometriosis

6. Survey Question: Indicate Your Preferred First-, Second-, and Third-Line Treatments for Severe Endometriosis

Abstract

• Endometriosis affects millions of women in the United States. What are the most common sites for endometrial lesions? What are the symptoms and complications of endometriosis? How does disease severity affect the level of symptoms?
• No new agent has been approved for the treatment of endometriosis in more than ten years. What are the most commonly prescribed agents for the treatment of endometriosis? How does treatment change with increasing disease severity? What are the strengths and drawbacks of existing treatments?
• Many existing treatments have a negative side-effect profile. What agents are currently in development for endometriosis? How do those treatments improve upon existing treatments? Are there opportunities for endometriosis agents in the treatment of other diseases?

• Overview of endometriosis: etiology and pathophysiology, symptoms, disease severity.
• Current treatments for endometriosis: Sanofi-Aventis’s Danocrine, Abbott Laboratories’/Takeda Pharmaceutical’s/TAP Pharmaceutical’s Lupron/Lupron Depot, AstraZeneca’s Zoladex, Pfizer’s Synarel, Pfizer’s Provera/Depo-Provera, surgical options.
• Medical practice: U.S. specialists surveyed to determine current prescribing patterns for various stages of endometriosis.
• Emerging treatments: a review of the endometriosis pipeline, Neurocrine Biosciences’ Elagolix, Repros Therapeutics’ Proellex (CDB-4124), KV Pharmaceuticals’ FP-1096.
• Outlook for the endometriosis market: 2007 market, expansion opportunities for endometriosis agents, outlook for emerging agents.
• Women’s Health Series: In 2007, the market for women’s reproductive health exceeded $23 billion worldwide. In the Women’s Health Series, we examine three specific markets, focusing on areas of unmet need and the best marketing strategies to ensure adoption of a new agent. We will provide insight from a variety of thought leaders on the current state of disease treatment and their opinions on the most promising agents currently in the pipeline.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.